Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$50.37 -1.0%	$55.78	$35.45 ▼ $61.69	$103.29B	0.38	4.30 million shs	3.52 million shs
RVMD Revolution Medicines	$147.21 -0.5%	$110.80	$34.00 ▼ $155.70	$31.44B	1.41	4.46 million shs	3.32 million shs
SNY Sanofi	$43.36 +0.0%	$46.39	$43.10 ▼ $54.75	$105.73B	0.35	2.85 million shs	2.22 million shs
TAK Takeda Pharmaceutical	$16.54 -0.1%	$17.94	$12.99 ▼ $18.90	$52.70B	-0.06	2.67 million shs	2.13 million shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	0.00%	-4.78%	-8.81%	-3.16%	+32.29%
RVMD Revolution Medicines	0.00%	+5.93%	+40.72%	+45.34%	+242.53%
SNY Sanofi	0.00%	+0.39%	-3.78%	-2.97%	-16.88%
TAK Takeda Pharmaceutical	0.00%	+1.65%	-11.21%	-4.65%	+8.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$50.37 -1.0%	$55.78	$35.45 ▼ $61.69	$103.29B	0.38	4.30 million shs	3.52 million shs
RVMD Revolution Medicines	$147.21 -0.5%	$110.80	$34.00 ▼ $155.70	$31.44B	1.41	4.46 million shs	3.32 million shs
SNY Sanofi	$43.36 +0.0%	$46.39	$43.10 ▼ $54.75	$105.73B	0.35	2.85 million shs	2.22 million shs
TAK Takeda Pharmaceutical	$16.54 -0.1%	$17.94	$12.99 ▼ $18.90	$52.70B	-0.06	2.67 million shs	2.13 million shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	0.00%	-4.78%	-8.81%	-3.16%	+32.29%
RVMD Revolution Medicines	0.00%	+5.93%	+40.72%	+45.34%	+242.53%
SNY Sanofi	0.00%	+0.39%	-3.78%	-2.97%	-16.88%
TAK Takeda Pharmaceutical	0.00%	+1.65%	-11.21%	-4.65%	+8.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	1.90	Reduce	$53.00	5.22% Upside
RVMD Revolution Medicines	3.10	Buy	$78.94	-46.38% Downside
SNY Sanofi	2.40	Hold	$51.00	17.62% Upside
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest RVMD, SNY, GSK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$52.00
5/1/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B)
5/1/2026	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
4/29/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
4/29/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
4/27/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
4/27/2026	SNY Sanofi	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2026	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
4/21/2026	RVMD Revolution Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
4/20/2026	SNY Sanofi	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$50.00
4/20/2026	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$43.07B	2.37	$5.94 per share	8.48	$11.57 per share	4.35
RVMD Revolution Medicines	$11.58M	2,702.54	N/A	N/A	$8.44 per share	17.44
SNY Sanofi	$49.35B	2.14	$7.06 per share	6.14	$35.10 per share	1.24
TAK Takeda Pharmaceutical	$30.09B	1.75	$3.18 per share	5.21	$14.39 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$7.54B	$3.85	10.99	9.82	2.58	17.82%	44.28%	11.49%	N/A
RVMD Revolution Medicines	-$1.13B	-$5.91	N/A	N/A	N/A	N/A	-63.10%	-48.13%	5/6/2026 (Estimated)
SNY Sanofi	$8.84B	$3.58	9.44	8.35	1.07	16.95%	13.39%	7.58%	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.24	10.35	13.03	N/A	2.58%	10.60%	5.21%	5/13/2026 (Estimated)

Latest RVMD, SNY, GSK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q4 2026	TAK Takeda Pharmaceutical	-$0.0754	N/A	N/A	N/A	$7.17 billion	N/A
5/6/2026	Q1 2026	RVMD Revolution Medicines	-$1.83	N/A	N/A	N/A	$2.43 million	N/A
2/25/2026	Q4 2025	RVMD Revolution Medicines	-$1.56	-$1.86	-$0.30	-$1.86	$3.89 million	N/A
2/5/2026	Q4 2025	GSK GSK	$0.64	$0.68	+$0.04	$0.42	$8.48 billion	$11.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.73	3.44%	-7.86%	44.94%	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.60	3.69%	+6.46%	44.69%	N/A
TAK Takeda Pharmaceutical	$0.50	3.01%	-2.41%	208.33%	N/A

Latest RVMD, SNY, GSK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GSK GSK	quarterly	$0.44	3.36%	5/15/2026	5/15/2026	7/9/2026
4/14/2026	SNY Sanofi	annual	$2.4225	5.59%	5/4/2026	5/4/2026	6/3/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	0.80	0.79	0.52
RVMD Revolution Medicines	0.16	7.14	7.14
SNY Sanofi	0.17	1.01	0.22
TAK Takeda Pharmaceutical	0.56	1.19	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
RVMD Revolution Medicines	94.34%
SNY Sanofi	14.03%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
RVMD Revolution Medicines	8.20%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	66,841	2.03 billion	1.83 billion	Optionable
RVMD Revolution Medicines	250	212.59 million	195.16 million	Optionable
SNY Sanofi	74,846	2.44 billion	2.41 billion	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

RVMD, SNY, GSK, and TAK Headlines

Recent News About These Companies

Takeda Pharmaceutical Co. $TAK Shares Sold by UBS Group AG

May 5 at 8:20 AM | marketbeat.com

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

May 5 at 8:15 AM | newswire.ca

A Cambridge pharma giant just cleared a key hurdle in treating rare immune disease

May 4 at 7:53 PM | masslive.comM

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

May 4 at 2:51 PM | pharmiweb.comP

Takeda's immune disease drug meets main goal of trial

May 4 at 2:51 PM | msn.com

Takeda's next-gen experimental immune drug comparable to approved treatment in study

May 4 at 2:51 PM | msn.com

Takeda's immune disease drug meets main goal of mid-to-late stage trial

May 4 at 8:12 AM | reuters.com

Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?

May 2 at 5:18 PM | insidermonkey.com

While Mass. biotech layoffs surge, this pharma company is on a $20B buying spree

May 2 at 7:14 AM | msn.com

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

April 30, 2026 | zacks.com

Takeda hires Jennifer Smoter as chief comms and governance officer

April 28, 2026 | mmm-online.comM

China Universal Asset Management Co. Ltd. Takes Position in Takeda Pharmaceutical Co. $TAK

April 25, 2026 | marketbeat.com

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

April 24, 2026 | zacks.com

Kawasaki Disease Market Analysis and Global Forecast Report 2025-2035 Featuring Prominent Players - Takeda Pharmaceutical, CSL Behring, Grifols, ADMA Biologics, and Octapharma

April 23, 2026 | finance.yahoo.com

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

April 14, 2026 | zacks.com

Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Strong-Buy at Wall Street Zen

April 11, 2026 | marketbeat.com

Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push

April 10, 2026 | tipranks.com

A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Mixed Pipeline News On DNL593 And Zasocitinib

April 8, 2026 | finance.yahoo.com

Takeda Pharmaceutical (NYSE:TAK) Upgraded to "Outperform" at Sanford C. Bernstein

April 8, 2026 | marketbeat.com

Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

April 6, 2026 | benzinga.com

Denali Regains DNL593 Rights After Takeda Collaboration Ends

April 4, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RVMD, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

$50.37 -0.53 (-1.04%)

Closing price 03:59 PM Eastern

Extended Trading

$50.51 +0.14 (+0.28%)

As of 07:56 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$147.21 -0.69 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$148.06 +0.85 (+0.58%)

As of 07:55 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Sanofi NASDAQ:SNY

$43.36 +0.01 (+0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$43.38 +0.02 (+0.05%)

As of 07:51 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$16.54 -0.02 (-0.10%)

Closing price 03:59 PM Eastern

Extended Trading

$16.49 -0.05 (-0.33%)

As of 06:57 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RVMD, SNY, GSK, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RVMD, SNY, GSK, and TAK Earnings

Compare Dividends

Latest RVMD, SNY, GSK, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RVMD, SNY, GSK, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RVMD, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

Revolution Medicines NASDAQ:RVMD

Sanofi NASDAQ:SNY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools